Unknown PHASE3 INTERVENTIONAL 2-arm NCT01249638

Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer

Sponsor: Ludwig-Maximilians - University of Munich

Conditions Colorectal Cancer Metastatic

Interventions Bevacizumab Capecitabine Irinotecan

Updated 6 times since 2017 Last updated: Mar 11, 2011 Started: Dec 31, 2010 Primary completion: Dec 31, 2013 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Colorectal Cancer Metastatic and is currently ongoing. Ludwig-Maximilians - University of Munich leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE3
Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ludwig-Maximilians - University of Munich
Roche Pharma AG

Data source: Ludwig-Maximilians - University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany